MA55140B1 - Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 - Google Patents
Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23Info
- Publication number
- MA55140B1 MA55140B1 MA55140A MA55140A MA55140B1 MA 55140 B1 MA55140 B1 MA 55140B1 MA 55140 A MA55140 A MA 55140A MA 55140 A MA55140 A MA 55140A MA 55140 B1 MA55140 B1 MA 55140B1
- Authority
- MA
- Morocco
- Prior art keywords
- ulcerative colitis
- antibody
- safe
- treatment
- effective method
- Prior art date
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 3
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000013264 Interleukin-23 Human genes 0.000 title 1
- 108010065637 Interleukin-23 Proteins 0.000 title 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des méthodes et des compositions pour le traitement cliniquement sûr et efficace de la colite ulcéreuse, en particulier de la colite ulcéreuse active modérée à sévère, chez des patients qui ont eu une réponse inadéquate ou qui sont intolérants à une thérapie conventionnelle ou existante par administration intraveineuse et/ou sous-cutanée d'un anticorps anti-il-12/il-23p40.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735501P | 2018-09-24 | 2018-09-24 | |
| PCT/IB2019/058098 WO2020065532A1 (fr) | 2018-09-24 | 2019-09-24 | Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55140A MA55140A (fr) | 2021-09-29 |
| MA55140B1 true MA55140B1 (fr) | 2023-09-27 |
Family
ID=88507038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55140A MA55140B1 (fr) | 2018-09-24 | 2019-09-24 | Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA55140B1 (fr) |
-
2019
- 2019-09-24 MA MA55140A patent/MA55140B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA55140A (fr) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MX2022015499A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
| MA46269B1 (fr) | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r | |
| MA58170B1 (fr) | Dérivés carboxy avec des proprietes anti-inflammatoires | |
| MA47119B1 (fr) | Administration de protéine à base de bactéries à virulence atténuée | |
| MA38406A1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
| MA45543B1 (fr) | Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations | |
| MA45811A (fr) | Méthodes et compositions de traitement de maladie. | |
| PH12021552763A1 (en) | Treatment and prevention of metabolic diseases | |
| DK202300038Y9 (da) | Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof | |
| EP4233861A3 (fr) | Compositions pour le traitement du tremblement essentiel | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| MA39294B1 (fr) | Polythérapie contre le cancer | |
| MA34815B1 (fr) | Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer | |
| MX2024001269A (es) | Inhibidores de rock2 y sus usos. | |
| MA56386B1 (fr) | Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale | |
| MA55140B1 (fr) | Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 | |
| MX2022009987A (es) | Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. | |
| EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
| MA50034B1 (fr) | Composition de stimulation ovarienne contrôlée | |
| Minami-Hori | Optic neuritis: case report | |
| Veeraraghavan et al. | Advances in rabies treatment: An experimental evaluation | |
| BR112022007314A2 (pt) | Método seguro e eficaz de tratamento de colite ulcerativa com anticorpos anti-il12/il23 | |
| MA51709B1 (fr) | Compositions comprenant des souches bactériennes |